• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

10/10 HLA 匹配的无关供者造血干细胞移植中供者年龄与 HLA-DP 匹配的相互作用。

Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT.

机构信息

Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

Division of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA.

出版信息

Blood Adv. 2024 Oct 22;8(20):5438-5449. doi: 10.1182/bloodadvances.2024013677.

DOI:10.1182/bloodadvances.2024013677
PMID:39008717
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11568750/
Abstract

In 10/10 HLA-matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) with calcineurin-inhibitor (CNI)-based prophylaxis, T-cell epitope DP-matched and permissive mismatched donors are associated with similar overall survival (OS) whereas donors with nonpermissive mismatches should be avoided. Younger unrelated donors are also favored over older donors. We explored outcomes associated with different combinations of DP-matching and donor age (dichotomized at 35 years) to further guide donor selection. Using a Center for International Blood and Marrow Transplant Research data set, we categorized 10 783 patients into 6 groups: DP-matched/younger donor (n = 1591), DP-matched/older donor (n = 526), permissive-mismatched/younger donor (n = 3845), permissive-mismatched/older donor (n = 1184), nonpermissive mismatched/younger donor (n = 2659), and nonpermissive mismatched/older donor (n = 978). We noted that younger donor age, rather than DP matching, was associated with better OS. Younger donors with permissive mismatches were associated with improved OS compared with older matched donors. Furthermore, younger donors with nonpermissive mismatches were associated with improved OS compared with older donors with permissive mismatches. Our study adds further information about the association of DP matching and donor age with HCT outcomes. Donor age should be prioritized over DP matching in patients undergoing 10/10 HLA-MUD with CNI prophylaxis. Among those with younger donors, permissive-mismatched or DP-matched donors are preferred over nonpermissive mismatched donors.

摘要

在 10/10 人类白细胞抗原(HLA)匹配的无关供者(MUD)造血细胞移植(HCT)中,使用钙调神经磷酸酶抑制剂(CNI)为基础的预防方案,T 细胞表位 DP 匹配和允许性错配供者与相似的总生存(OS)相关,而应避免非允许性错配的供者。年轻的无关供者也优于年长的供者。我们探讨了 DP 匹配和供者年龄(以 35 岁为界分为两组)不同组合与结局的关系,以进一步指导供者选择。利用国际血液和骨髓移植研究中心(CIBMTR)的数据集,我们将 10783 例患者分为 6 组:DP 匹配/年轻供者(n=1591)、DP 匹配/年长供者(n=526)、允许性错配/年轻供者(n=3845)、允许性错配/年长供者(n=1184)、非允许性错配/年轻供者(n=2659)和非允许性错配/年长供者(n=978)。我们注意到,供者年龄而不是 DP 匹配与更好的 OS 相关。具有允许性错配的年轻供者与年长匹配供者相比,OS 改善。此外,与年长具有允许性错配的供者相比,具有非允许性错配的年轻供者与 OS 改善相关。我们的研究进一步提供了关于 DP 匹配和供者年龄与 HCT 结局关系的信息。在接受 10/10 HLA-MUD 和 CNI 预防方案的患者中,供者年龄应优先于 DP 匹配。在具有年轻供者的患者中,与非允许性错配供者相比,允许性错配或 DP 匹配的供者更受欢迎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/c8d8f5c3956b/BLOODA_ADV-2024-013677-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/f02806627449/BLOODA_ADV-2024-013677-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/7d19fbac50dd/BLOODA_ADV-2024-013677-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/6e385a0dcb87/BLOODA_ADV-2024-013677-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/c8d8f5c3956b/BLOODA_ADV-2024-013677-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/f02806627449/BLOODA_ADV-2024-013677-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/7d19fbac50dd/BLOODA_ADV-2024-013677-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/6e385a0dcb87/BLOODA_ADV-2024-013677-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5873/11568750/c8d8f5c3956b/BLOODA_ADV-2024-013677-gr3.jpg

相似文献

1
Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT.10/10 HLA 匹配的无关供者造血干细胞移植中供者年龄与 HLA-DP 匹配的相互作用。
Blood Adv. 2024 Oct 22;8(20):5438-5449. doi: 10.1182/bloodadvances.2024013677.
2
Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes.无关供者年龄与 HLA 肽结合基序匹配状态联合对 HCT 结局的影响。
Blood Adv. 2024 May 14;8(9):2235-2242. doi: 10.1182/bloodadvances.2024012669.
3
Haploidentical Versus Mismatched Unrelated Donor Hematopoietic Cell Transplantation: HLA Factors and Donor Age Considerations.单倍体相合与非血缘 HLA 不全相合造血干细胞移植:HLA 因素和供者年龄的考虑。
Transplant Cell Ther. 2024 Sep;30(9):909.e1-909.e11. doi: 10.1016/j.jtct.2024.07.005. Epub 2024 Jul 10.
4
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.无关供者造血细胞移植受者 HLA-DPB1 中 T 细胞表位匹配的效果:一项回顾性研究。
Lancet Oncol. 2012 Apr;13(4):366-74. doi: 10.1016/S1470-2045(12)70004-9. Epub 2012 Feb 15.
5
SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection.SOHO 最新进展和下一步问题 | 供者选择的现状和未来方向。
Clin Lymphoma Myeloma Leuk. 2024 Dec;24(12):821-826. doi: 10.1016/j.clml.2024.05.011. Epub 2024 May 14.
6
Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant.10/10 HLA 配型相合的无关供受者配对中 HLA-DPB1 错配对异基因干细胞移植后临床结局的影响。
Eur J Haematol. 2017 Sep;99(3):275-282. doi: 10.1111/ejh.12916. Epub 2017 Jul 21.
7
Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations.单倍体相合与 HLA 匹配的同胞供者造血干细胞移植加 PTCy 预防:HLA 因素和供者年龄的考虑。
Blood Adv. 2024 Oct 22;8(20):5306-5314. doi: 10.1182/bloodadvances.2024013853.
8
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.移植后环磷酰胺为主的移植物抗宿主病预防方案可减轻匹配或不匹配非亲缘供者使用导致的结局差异。
J Clin Oncol. 2024 Oct;42(28):3277-3286. doi: 10.1200/JCO.24.00184. Epub 2024 Jul 17.
9
Existence of HLA-Mismatched Unrelated Donors Closes the Gap in Donor Availability Regardless of Recipient Ancestry.HLA 错配非亲缘供者的存在缩小了供者来源的差距,而与受者的种族无关。
Transplant Cell Ther. 2023 Nov;29(11):686.e1-686.e8. doi: 10.1016/j.jtct.2023.08.014. Epub 2023 Aug 14.
10
Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.HLA-DPB1 T细胞表位匹配与非亲缘造血细胞移植结果之间的风险关联独立于HLA-DPA1。
Bone Marrow Transplant. 2014 Sep;49(9):1176-83. doi: 10.1038/bmt.2014.122. Epub 2014 Jun 23.

引用本文的文献

1
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT.2023年欧洲血液与骨髓移植学会(EBMT)关于造血细胞移植和细胞疗法的报告。异基因造血细胞移植在髓系恶性肿瘤中的使用增加,以及嵌合抗原受体T细胞(CAR-T)疗法的使用增加,而自体造血细胞移植的使用则相应减少。
Bone Marrow Transplant. 2025 Apr;60(4):519-528. doi: 10.1038/s41409-025-02524-2. Epub 2025 Feb 12.
2
What makes a good Samaritan: age, HLA matching, or both?是什么造就了一个善良的撒玛利亚人:年龄、人类白细胞抗原匹配,还是两者兼具?
Blood Adv. 2024 Oct 22;8(20):5435-5437. doi: 10.1182/bloodadvances.2024014188.

本文引用的文献

1
Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes.无关供者年龄与 HLA 肽结合基序匹配状态联合对 HCT 结局的影响。
Blood Adv. 2024 May 14;8(9):2235-2242. doi: 10.1182/bloodadvances.2024012669.
2
Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation.HLA 免疫肽组对异基因供体移植后白血病患者生存的影响。
J Clin Oncol. 2023 May 1;41(13):2416-2427. doi: 10.1200/JCO.22.01229. Epub 2023 Jan 20.
3
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
ABO 血型不合与急性白血病异基因造血细胞移植结局的关系。
Am J Hematol. 2023 Apr;98(4):608-619. doi: 10.1002/ajh.26834. Epub 2023 Jan 16.
4
A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation.一组结构相似的HLA-DPB1等位基因核心群体在造血细胞移植后驱动免疫许可。
Blood. 2022 Aug 11;140(6):659-663. doi: 10.1182/blood.2022015708.
5
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.老年亲缘供者与年轻无关供者异基因造血细胞移植治疗骨髓增生异常综合征患者的复发和无病生存。
JAMA Oncol. 2022 Mar 1;8(3):404-411. doi: 10.1001/jamaoncol.2021.6846.
6
Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning.基于贝叶斯机器学习的造血干细胞移植最优供者选择。
JCO Clin Cancer Inform. 2021 May;5:494-507. doi: 10.1200/CCI.20.00185.
7
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.移植后环磷酰胺与巨细胞病毒感染增加有关:CIBMTR 分析。
Blood. 2021 Jun 10;137(23):3291-3305. doi: 10.1182/blood.2020009362.
8
Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM.在 HCT 中,允许的 HLA-DPB1 错配取决于免疫肽组的差异和 HLA-DM 的编辑。
Blood. 2021 Feb 18;137(7):923-928. doi: 10.1182/blood.2020008464.
9
Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation.HLA-DP 表达在异基因供体移植后移植物抗宿主病中的作用。
J Clin Oncol. 2020 Aug 20;38(24):2712-2718. doi: 10.1200/JCO.20.00265. Epub 2020 Jun 1.
10
Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR.无关供者和脐带血造血细胞移植的选择:来自 NMDP/CIBMTR 的指南。
Blood. 2019 Sep 19;134(12):924-934. doi: 10.1182/blood.2019001212. Epub 2019 Jul 10.